Loading...

23ANDME HOLDING CO Investments/Divestments 8-K Filing

23ND

23ANDME HOLDING CO

()

2023 8-K

Show Summary

Summary

Leadership Change

Bankruptcy Update

Asset Acquisitions

Asset Acquisitions

Asset Acquisitions

Chapter 11 Bankruptcy

Bankruptcy Filing

Bankruptcy Filing

Financial Results

Financial Results

Compliance Regained

Board Expansion

Stock Split Announcement

Nasdaq Compliance Issue

Board Resignations

Stockholder Meeting

Financial Results and Resig...

Investor Presentation

Preliminary Phase 2 Data An...

Retirement and Consulting A...

Earnings Report

Management Changes

Earnings Report

FDA Clearance for Cancer Tr...

Regulation FD Disclosure

Financial Results Announcement

Clinical Trial Data Announc...

Drug discovery and collabor...

Resignation of Vice President

Data Security Incident

Equity Awards Granted

Amended and Restated 2021 I...

Financial Results and Workf...

Workforce Reduction

Financial Results Announcement

Investor Presentation

Phase 1 study results annou...

Financial Results Announcement

Sales Agreement

External Links:

23andMe Holding Co. announced results from the Phase 1 portion of its Phase 1/2a study evaluating 23ME-00610, an investigational antibody targeting CD200R1.

AI Assistant

23ANDME HOLDING CO

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.